Intellia Therapeutics NTLA Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's investing cash flow?
- Intellia Therapeutics (NTLA) reported investing cash flow of $66.31M in Q1 2026.
- How has Intellia Therapeutics's investing cash flow changed year-over-year?
- Intellia Therapeutics's investing cash flow decreased by 29.7% year-over-year, from $94.33M to $66.31M.
- What is the long-term trend for Intellia Therapeutics's investing cash flow?
- Over 2 years (2021 to 2025), Intellia Therapeutics's investing cash flow has grown at a -35.6% compound annual growth rate (CAGR), from -$550.78M to $228.77M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.